Project Grant R01HL183340
Award Date 8/25/26
Completion Date 5/31/31
Dollars Obligated $835K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $850,669 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate place-based drivers of health in sickle cell disease pathogenesis. The project will identify and quantify mechanisms linking neighborhood and personal exposures—including crime-related stressors, unhealthy food access, temperature, airborne particulates, and housing conditions—to clinical...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $746,979 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of pain in sickle cell disease. The research uses transgenic mice with sickle cell disease to study how vaso-occlusive crises trigger severe pain. The project examines the role of lysophosphatidic acid (LPA), a pain mediator elevated during hypoxia-induced vaso-occlusion, and tests...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Heart, Lung, and Blood Institute awarded Yale University $841,906 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, to conduct the SPIRIT-2 Study examining high-impact chronic pain in sickle cell disease. The study addresses three critical gaps in sickle cell disease pain management: identifying risk factors for sustained high-impact chronic pain and poor long-term outcomes; developing patient-centered endpoints to assess intervention efficacy from...
- The National Heart, Lung, and Blood Institute awarded the University of Texas at Dallas $641,538 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing R01HL181083) to investigate gut microbiome targets for sickle cell disease pain management. The research addresses chronic pain in individuals with sickle cell disease, a leading complication that persists despite advances in disease-modifying and curative therapies and is often managed with...
- The National Institute of Neurological Disorders and Stroke awarded the University of Texas at Arlington $2,083,992 on September 18, 2025, to conduct longitudinal collection and computational modeling of health data in Black adolescents and young adults with sickle cell disease, with an ultimate completion date of August 31, 2030. The project, titled "Modeling Inter-Individual Differences to Address Pain of Sickle Cell Disease (MIDAS)," is supported under the Drug Use and Addiction...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $232,836 on December 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomarkers of ischemic risk in adults with sickle cell disease using non-invasive quantitative neuroimaging methods. The research uses arterial spin labeling MRI and other quantitative imaging techniques to test hypotheses regarding cerebral oxygen utilization in patients with sickle cell disease...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $453,834 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a tissue-selective modified mRNA delivery system for cardiac injury prevention and treatment. The recipient is developing CMSMRTS 143-122, a cardiomyocyte-selective modified mRNA system encapsulated in lipid nanoparticles for intravenous administration. The system targets acid ceramidase mRNA...
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Heart, Lung, and Blood Institute awarded Duke University $238,516 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct admixture mapping of genetic modifiers in sickle cell disease. The research leverages the National Heart, Lung, and Blood Institute's TOPMed program, which includes multiple cross-sectional adult sickle cell disease cohorts totaling more than 4,000 participants with whole genome sequencing data and extensive clinical...